NCT06447779进行中（未招募）3 期
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above
MAXVAX Biotechnology Limited Liability Company4 个研究点 分布在 1 个国家目标入组 25,000 人开始时间: 2024年7月13日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25,000
- 试验地点
- 4
- 主要终点
- Incidence of confirmed Herpes Zoster(HZ) Cases per person years in subjects aged 40 years and older
研究概览
简要总结
The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.
详细描述
A total of 25000 adults aged 40 years and older will be enrolled, stratified into 40-49, 50-59, 60-69 and ≥70 years of age. All subjects will randomly receive investigational vaccine or placebo at a ratio of 1:1. Efficacy and safety will be assessed in all subjects, while immunogenicity will be assessed in a subset of 1250 subjests in a selected trial site.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A male or famale permanent resident aged 40 years and older at enrollment, with valid identity;
- •Subjects voluntarily agree to participate in the study and signed an informed consent;
- •Be able to understand clinical trials, participate in all scheduled visits and comply with the protocol requirements(e.g. completion of the diary cards/questionnaires, return for follow-up visits, have regular contact to allow evaluation during the study);
- •Women of childbearing potential plan to aviod pregnancy and are willing to use effcetive contraception(e.g. oral contraceptive pills, injectable progestogen, percutaneous contraceptive patches, implants of levonorgestrel, intrauterine device, female and male sterilization or abstinence) within 12 months after the last vaccination, and the uses of the rhythm method alone, withdrawal alone, and emergency contraception, are not acceptable.
排除标准
- •Axillary temperature>37.0℃;
- •Current or history of herpes zoster;
- •Previous vaccination against varicella or herpes zoster (either registered product or participation in a previous vaccine study);
- •Pregnant (urine pregnancy test was positive) or lactating female;
- •Receipt of live vaccine within 28 days, or any other vaccine within 14 days prior to vaccination;
- •Receipt of immunoglobulin or intravenous immunoglobulin during 3 months before vaccination to 1 month post the last vaccination;
- •Acute diseases or acute exacerbation of chronic disease within 3 days before vaccination;
- •Receipt of antipyretic, analgesic and allergy drugs within 3 days before vaccination, except enteric-coated aspirin for cardiovascular diseases prevention;
- •A known allergy to any components of the study vaccine, or history of severe allergy (e.g. Anaphylactic shock, allergic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, Arthus reaction, severe urticaria) to any previous vaccination;
- •Allergy to aminoglycoside antibiotics;
- •History of convulsions, epilepsy, encephalopathy (e.g. congenital brain dysplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebral infarction, brain infection disease, nerve tissue damage caused by chemical drug poisoning), mental illness and family history, and other serious neurological diseases;
- •Asplenia or functional asplenia, or splenectomy caused by any condition;
- •Primary or secondary impairment of immune function, diagnosed congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease or other autoimmune diseases;
- •Receipt of immunosuppressive therapy (e.g. long-term use of systemic glucocorticoid ≥14 days, dose ≥2mg/kg/day or ≥20mg/day prednisone or equivalent dose) during 6 months before vaccination to 1 minth post the last vaccination, but inhaled, nasal spray, intra-articular, eyedrops, ointment and other topical steroids are acceptable;
- •Receipt of long-acting immune-modifying drugs (e.g. Infliximab) within 6 months before vaccination or during the study period;
- •Severe chronic disease, including but not limited to, severe cardiovascular disease(e.g. Pulmonary heart disease, Pulmonary Edema), severe liver or kidney disease, or diabetes with complication;
- •History of thrombocytopenia or other coagulation disorders, which may cause intramuscular injection contraindications;
- •Abnormal and uncontrlled blood pressure during physical examination before vaccination (for subjects aged 40-59: systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mmHg; for subjects aged ≥60, systolic pressure ≥ 150 mmHg and/or diastolic pressure ≥ 100 mmHg);
- •History of drug abuse (narcotic drugs, psychotropic drugs);
- •Current skin infections, in the opinion of the investigator, might interfere with the efficacy evaluation;
- •Current or history of malignant tumors, except papillary thyroid carcinoma;
- •Receipt of investigational products (drugs or vaccines) within 6 months before vaccination;
- •Planned participation in another clinical study during the study period;
- •Any condition that, in the opinion the investigator, may affect the safety of the subject or the evaluation of the study results.
研究组 & 干预措施
Vaccine Group
Experimental
Subjects will receive Recombinant Zoster Vaccine (CHO cell) according to a 0, 2-month schedule
干预措施: Recombinant Zoster Vaccine (CHO Cell) (Biological)
Placebo Group
Placebo Comparator
Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
干预措施: NaCl solution Placebo (Biological)
结局指标
主要结局
Incidence of confirmed Herpes Zoster(HZ) Cases per person years in subjects aged 40 years and older
时间窗: 30 days after the last vaccination
A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the Endpoint Adjudication Committee (EAC), consisting of physicians with HZ expertise.
次要结局
- Seroresponse rate of anti-gE antibody and anti-VZV antibody in immunogenicity subset(30 days after the last vaccination)
- Seropositivity rate of anti-gE antibody and anti-VZV antibody in immunogenicity subset(At 1, 12, 24 and 36 months after the last vaccination)
- Four-fold increase rate of anti-gE antibody and anti-VZV antibody in immunogenicity subset(30 days after the last vaccination)
- Number of Participants With potential Immune Mediated Disorders(From the day of first vaccination up to 12 months after last vaccination)
- Incidence of confirmed Herpes Zoster(HZ) Cases per person years in different age group.(30 days after the last vaccination)
- Geometric Mean Fold Rise (GMFR) of anti-gE antibody and anti-VZV antibody in immunogenicity subset(At 1, 12, 24 and 36 months after the last vaccination)
- Cell-Mediated Immunity (CMI) response(30 days after the last vaccination)
- Vaccine Response Rate (VRR)(30 days after the last vaccination)
- Number of Participants With solicited local symptoms(Within 7 days after each vaccination)
- Number of Participants With Serious Adverse Events(From the day of first vaccination up to 12 months after last vaccination)
- Incidence of any and severe Postherpetic Neuralgia (PHN) cases per person years in subjects aged 40 years and older, 40-49years , 50-59 years , 60-69 years and ≥70 years , with confirmed HZ.(30 days after the last vaccination)
- Number of Participants With solicited general symptoms.(Within 7 days after each dose)
- Geometric Mean Concentration(GMC) of anti-gE antibody and anti-VZV antibody in immunogenicity subset(At 1, 12, 24 and 36 months after the last vaccination)
- Number of Participants With unsolicited adverse events(During 30 days after each vaccination)
研究者
研究点 (4)
Loading locations...
相似试验
招募中
3 期
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster VaccineVaccine-Preventable DiseasesHerpes ZosterNCT06088745Beijing Luzhu Biotechnology Co., Ltd.4
招募中
不适用
Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant RecipientsImmunosuppressionVaccine Response ImpairedNCT06262776Central Adelaide Local Health Network Incorporated160
招募中
1 期
A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster VaccineVaccine-Preventable DiseasesHerpes ZosterNCT05750017Beijing Luzhu Biotechnology Co., Ltd.66
已完成
3 期
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)Herpes ZosterNCT00231816Merck Sharp & Dohme LLC763
已完成
2 期
A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background MethotrexateRheumatoid ArthritisNCT02147587Pfizer112